Genprex

Tagged: Oncology

Genprex Provides Business Update and Outlook for 2024 

Acclaim-1 Phase 2a and Acclaim-3 Phase 1 clinical studies opening for enrollment in January 2024

Poised for FDA guidance regarding diabetes gene therapy program in 2024

Read More

Genprex In-Licenses Additional Gene Therapy Technologies for Treatment of Lung Cancer

Amendment to existing worldwide, exclusive license agreement expands Genprex’s oncology franchise

Read More